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Background and Purpose—Prediction models may help physicians to stratify patients with high and low risk for 
periprocedural complications or long-term stroke risk after carotid artery stenting or carotid endarterectomy. We aimed to 
evaluate external performance of previously published prediction models for short- and long-term outcome after carotid 
revascularization in patients with symptomatic carotid artery stenosis.
Methods—From a literature review, we selected all prediction models that used only readily available patient characteristics 
known before procedure initiation. Follow-up data from 2184 carotid artery stenting and 2261 carotid endarterectomy 
patients from 4 randomized trials (EVA-3S [Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe 
Carotid Stenosis], SPACE [Stent-Protected Angioplasty Versus Carotid Endarterectomy], ICSS [International Carotid 
Stenting Study], and CREST [Carotid Revascularization Endarterectomy Versus Stenting Trial]) were used to validate 
23 short-term outcome models to estimate stroke or death risk ≤30 days after the procedure and the original outcome 
measure for which the model was developed. Additionally, we validated 7 long-term outcome models for the original 
outcome measure. Predictive performance of the models was assessed with C statistics and calibration plots.
Results—Stroke or death ≤30 days after the procedure occurred in 158 (7.2%) patients after carotid artery stenting and in 84 
(3.7%) patients after carotid endarterectomy. Most models for short-term outcome after carotid artery stenting (n=4) or carotid 
endarterectomy (n=19) had poor discriminative performance (C statistics ranging from 0.49–0.64) and poor calibration with small 
absolute risk differences between the lowest and highest risk groups and overestimation of risk in the highest risk groups. Long-
term outcome models (n=7) had a slightly better performance with C statistics ranging from 0.59 to 0.67 and reasonable calibration.
Conclusions—Current models did not reliably predict outcome after carotid revascularization in a trial population of patients 
with symptomatic carotid stenosis. In particular, prediction of short-term outcome seemed to be difficult. Further external 
validation of existing prediction models or development of new prediction models is needed before such models can be used 
to support treatment decisions in individual patients.   (Stroke. 2018;49:00-00. DOI: 10.1161/STROKEAHA.117.020486.)
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In 2015, around 5.4 million patients worldwide suffered a first-ever ischemic stroke.1 About 10% to 15% of these 
strokes are caused by thromboembolism from an atheroscle-
rotic plaque at the carotid bifurcation or the internal carotid 
artery (ICA).2 Such strokes can be prevented by surgical 
excision of the plaque with carotid endarterectomy (CEA) 
or by carotid artery stenting (CAS).3 The benefit of carotid 
revascularization for an individual patient depends on the bal-
ance between the long-term risk of vascular complications on 
medical treatment and the periprocedural risk of these com-
plications. Risk prediction models can be used to predict the 
absolute risk of periprocedural stroke or death after CEA or 
CAS in an individual patient.
Over the past decade, many prediction models for out-
come after carotid revascularization have been developed. In 
a recent literature review, we identified 46 prediction models 
that can be applied to patients with symptomatic or asymp-
tomatic ICA stenosis.4 Only a few of these prediction models 
were validated in independent patient populations, although 
external validation is an essential step in prediction model 
development that should be performed before a model can be 
implemented in clinical practice.5,6
Therefore, we aimed to assess the external performance of 
prediction models for short-term and long-term outcome after 
carotid revascularization that were identified with our litera-
ture review. We selected prediction models that used readily 
available patient characteristics that were known before pro-
cedure initiation. We validated these models in patients with 
symptomatic ICA stenosis enrolled in randomized controlled 
trials comparing CAS versus CEA.
Methods
Selection of Prediction Models
In the literature review, we identified 46 prediction models for clinical 
outcome after CAS or CEA. Sixteen models were excluded from the 
current study; 10 of these models used procedural characteristics (eg, 
duration of procedure), 3 models predicted risk of myocardial infarc-
tion or other cardiac complications only, and 3 models did not contain 
sufficient information to validate the model (Figure). Details of the 
literature review and references of the excluded studies are provided 
in the online-only Data Supplement.
The 30 models we selected for external validation included 23 
short-term outcome models (4 CAS and 19 CEA models) and 7 long-
term outcome models (2 CAS, 4 CEA, and 1 combined model). We 
classified models that predicted in-hospital risk or risk up to 30 days 
after the procedure as short-term outcome models, whereas models 
that predicted risk after longer follow-up were classified as long-term 
outcome models. Tables I and II in the online-only Data Supplement 
provide an overview of the predictors used in each prediction model, 
the predicted outcome measure, and a description and key baseline 
characteristics of the development cohorts. The most often predicted 
outcome measure was a composite of stroke or death for the short-term 
outcome models and mortality for the long-term outcome models.
Validation Population
The validation population consisted of patients included in 4 random-
ized controlled trials that are pooled by the CSTC (Carotid Stenosis 
Trialists’ Collaboration): the EVA-3S (Endarterectomy Versus 
Angioplasty in Patients With Symptomatic Severe Carotid Stenosis) 
trial,7 the SPACE (Stent-Protected Angioplasty versus Carotid 
Endarterectomy) trial,8 the ICSS (International Carotid Stenting 
Study),9 and the CREST (Carotid Revascularization Endarterectomy 
Versus Stenting Trial).10 Collectively, these trials randomly allocated 
4754 patients with symptomatic carotid artery stenosis of ≥50% accord-
ing to the North American Symptomatic Carotid Endarterectomy Trial 
criteria11 to undergo either CAS or CEA. Data on individual patient 
characteristics such as demographics, comorbidities, and degree of ste-
nosis were collected at baseline in all 4 trials. Details on study design 
and methods are described elsewhere.7–10 The CSTC welcomes other 
investigators to propose analyses of the pooled data. Such analyses 
could then be performed in close collaboration with the CSTC Steering 
Committee.
We excluded patients in whom the randomly allocated procedure 
was not completed or who suffered a stroke before procedure initia-
tion. This resulted in 2184 patients who underwent CAS and 2261 
patients who underwent CEA for analyses.
Outcome Measures
All patients in the validation population were followed up for the 
occurrence of stroke or death. Stroke was uniformly defined in all 4 
trials as the occurrence of acute focal neurological deficit with symp-
toms that lasted for >24 hours caused by ischemic or hemorrhagic 
cerebrovascular disturbance.
We used stroke or death risk within 30 days after the procedure as 
the primary outcome for all short-term outcome models. In addition, 
we externally validated all short-term outcome models for the origi-
nal outcome measure that was used in the model development study, 
if data on this outcome measure were available in our validation pop-
ulation. We externally validated all long-term outcome models for 
the original outcome measure. Three long-term outcome models pre-
dicted death occurring within 5 years after the procedure (Hoke 2012, 
Conrad 2013, Wallaert 2013); we externally validated these models 
with data from EVA-3S and ICSS only, because sufficiently long-
term follow-up data from these 2 trials were available to the CSTC.
Statistical Analysis
We first matched predictors and outcome measures of each prediction 
model to variables in the validation population. Proxies were used in 
case a direct match was unavailable (Description of proxies is available 
in the online-only Data Supplement). A value of zero was assigned for 
predictors that were not available in any of the 4 trials (indicated with 
an asterisk in Table I in the online-only Data Supplement).
For most predictors, the proportion of patients with missing 
data within each trial was low (<2%), although more missing values 
occurred for antiplatelet use (49%) and for presence of contralateral 
ICA occlusion (4%). However, some predictors have not been mea-
sured in one or more of the 4 trials and are thus systematically missing 
Figure. Flowchart of prediction models selected for external validation 
from previous literature review. Models for short-term outcome predict risk 
≤30 d after the procedure; models for long-term outcome predict risk >30 
d after the procedure. CAS indicates carotid artery stenting; CEA, carotid 
endarterectomy; and MI, myocardial infarction.
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in some of the trials (Table III in the online-only Data Supplement). 
Also, the occurrence of myocardial infarction during follow-up was 
not available in CREST. Missing data were imputed with the MICE 
package in R using source trial as predictive variable in the imputa-
tion model and creating 10 imputed data sets.
Per model, we applied the original regression formula to calculate 
the risk of the outcome for each patient in the validation population. 
In case the original regression formula was unavailable despite con-
tacting the authors, and a risk score was reported in the original pub-
lication, we assessed the performance of this risk score.
Predictive performance of the models was analyzed with dis-
crimination and calibration. Discrimination describes the ability of a 
model to distinguish between someone with and without the outcome 
and was examined with the C statistic. A C statistic of 0.5 reflects a 
model with no discriminative ability, and a value of 1.0 indicates per-
fect discriminative ability. For each prediction model, we calculated 
the C statistic in each trial separately and performed a random-effects 
meta-analysis of the results to account for heterogeneity between the 
4 trials. Subsequently, we pooled the C statistics of each multiply 
imputed data set with Rubin’s rules.12 Calibration indicates whether 
the predicted risks of the outcome correspond with the observed risks 
in the validation population. This was examined with calibration plots 
and calibration slopes. Differences between the incidence of the out-
come in the validation population and the development cohorts are 
known to influence calibration. Therefore, we recalibrated the models 
for which we applied the original regression formula to the incidence 
of the outcome in the validation population by adjusting the original 
intercept (for logistic regression models) or baseline hazard (for Cox 
regression models).13,14 Here, we present calibration of the models 
after recalibration. Calibration plots before recalibration are provided 
in Figure I in the online-only Data Supplement.
We performed 2 sensitivity analyses. First, we externally vali-
dated each prediction model in each of the 4 trials separately. Second, 
we externally validated each model in complete cases (ie, patients 
who had data on all variables available that were used by the predic-
tion model; a value of zero was assigned for predictors that were not 
available in any of the 4 trials). Statistical analyses were performed 
with SPSS version 22 and R-3.3.2.
Results
Validation Population and Occurrence of Outcome
Stroke or death within 30 days after revascularization occurred 
in 158 (7.2%) of the patients who underwent CAS and in 84 
(3.7%) patients who underwent CEA. Stroke or death within 
1 year occurred in 248 (11.4%) patients after CAS and in 163 
(7.2%) patients after CEA.
Baseline characteristics of the development and validation 
populations are presented in Tables II and III in the online-only 
Data Supplement. In both the development and validation pop-
ulations, about two-thirds of patients were men and the mean 
age was 70 years. All patients in the validation population had 
symptomatic ICA stenosis, whereas only 2 models were spe-
cifically developed in symptomatic patients, 8 in asymptom-
atic patients, and 19 in both symptomatic and asymptomatic 
patients (Table II in the online-only Data Supplement).
We applied the original regression formula for 22 of the 
30 models. Eight models did not report the original regression 
equation, and the authors were unable to provide additional 
information on request; therefore, we assessed performance 
of the risk scores.
CAS Short-Term Outcome Models
C statistics for the 4 short-term outcome models after CAS 
ranged from 0.55 to 0.64 for our primary outcome in the 
validation population and were consistently lower than 
the corresponding C statistics in the development cohorts 
(Table). The Hawkins 2012 model had the highest C sta-
tistic in the validation population. However, the calibration 
curves of all 4 models deviated from the ideal calibration 
slope for patients within the highest risk categories (Figure 
II in the online-only Data Supplement). Both age and history 
of stroke or symptomatic status were used as predictors in 
the 2 models with best model performance (Hawkins 2012, 
Wimmer 2012).
CEA Short-Term Outcome Models
For the 19 short-term outcome models after CEA, C sta-
tistics ranged from 0.49 to 0.60 for our primary outcome, 
which indicates poor discriminative performance (Table). 
The Bekelis 2013b model had reasonable calibration with a 
calibration slope (0.88) near the ideal value of 1.0. However, 
the curve was narrow with an absolute risk difference of only 
5% between patients in the lowest and highest risk groups, 
similar to most other short-term outcome models after CEA. 
This indicates that these models cannot distinguish between 
patients with a low or high risk of the outcome (Figure II 
in the online-only Data Supplement). The Kuhan 2001 and 
Bennett 2015 models were probably overfitted to the original 
development population, which is reflected by the rather flat 
calibration curves with too low predictions for patients in the 
lowest risk categories and too high predictions for patients in 
the highest risk categories. The calibration curves of the other 
models deviated from the ideal calibration curve for predicted 
risks >5%. Most frequently used predictors in the models with 
most reasonable performance (Calvillo-King 2010a, Bekelis 
2013b) were history of transient ischemic attack or stroke and 
history of coronary artery disease.
CAS or CEA Long-Term Outcome Models
We externally validated 7 prediction models for long-
term outcome after CAS or CEA. C statistics ranged from 
0.59 to 0.67 and were clearly higher compared with those 
of the short-term outcome models (Table). All calibration 
plots showed increasing observed risk of the outcome with 
increasing predicted risk (Figure II in the online-only Data 
Supplement). For the long-term outcome models after CAS, 
the Hoke 2012 model had the highest C statistic in combina-
tion with a reasonable calibration curve; for the long-term 
outcome models after CEA, the Wallaert 2013 model had 
best discrimination and calibration. Age, diabetes mellitus, 
and heart failure were used as predictors in both models with 
best external performance.
Sensitivity Analyses
External validation in each of the 4 trials separately yielded 
results comparable to our main analyses, although results 
were less precise. C statistics and calibration curves var-
ied more between the trials for the prediction models after 
CEA than for the models after CAS, which may be caused 
by the low number of outcome events per trial after CEA 
(data not shown). Performance of the prediction models 
in a complete case analysis also showed results compa-
rable to our main results (Table IV in the online-only Data 
Supplement).
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Table. Discrimination (C Statistic) of Each Prediction Model in the Validation Population and in the Original Model Development Study
Prediction Model
Model Development Study External Validation
C Statistic (95% CI) in 
Development Cohort Original Outcome Measure
C Statistic (95% CI) for 
Original Outcome Measure
C Statistic (95% CI) for 
Stroke or Death
CAS short-term models
  Hofmann 2006a 0.69 (NR) Stroke, MI, or death 0.55 (0.50–0.60) 0.55 (0.50–0.59)
  Hofmann 2006b 0.73 (NR) Stroke, MI, or death 0.55 (0.50–0.60) 0.55 (0.50–0.59)
  Hawkins 2012 0.71 (NR) Stroke or death 0.64 (0.60–0.69) 0.64 (0.60–0.69)
  Wimmer 2012 0.69 (NR) Stroke or death 0.60 (0.56–0.65) 0.60 (0.56–0.65)
CEA short-term models
  McCrory 1993 NR Stroke, MI, or death 0.53 (0.47–0.60) 0.54 (0.48–0.61)
  Kucey 1998 0.58 (NR) Stroke or death 0.53 (0.47–0.59) 0.53 (0.47–0.59)
  Rothwell 1999 NR Major stroke or death 0.46 (0.28–0.64) 0.52 (0.44–0.61)
  Kuhan 2001 NR Major stroke or death 0.40 (0.14–0.66) 0.56 (0.48–0.64)
  Tu 2003 NR Stroke or death 0.53 (0.47–0.59) 0.53 (0.47–0.59)
  Matsen 2005 0.66 (NR) Mortality 0.51 (0.18–0.84) 0.49 (0.42–0.56)
  Goodney 2008 0.71 (NR) Stroke or death 0.55 (0.47–0.63) 0.55 (0.47–0.63)
  Calvillo-King 2010a 0.62 (NR) Stroke or death 0.60 (0.54–0.66) 0.60 (0.54–0.66)
  Calvillo-King 2010b 0.64 (NR) Stroke 0.60 (0.54–0.66) 0.60 (0.54–0.66)
  Calvillo-King 2010c NR Stroke or death 0.59 (0.54–0.65) 0.59 (0.54–0.65)
  Bekelis 2013a 0.64 (0.62–0.66) Stroke, MI, or death 0.55 (0.48–0.63) 0.55 (0.48–0.62)
  Bekelis 2013b 0.63 (0.61–0.65) Stroke 0.57 (0.49–0.65) 0.57 (0.49–0.65)
  Bekelis 2013c 0.74 (0.71–0.77) Mortality 0.50 (0.07–0.93) 0.55 (0.47–0.62)
  Gupta 2013 0.64 (NR) Stroke, MI, or death 0.56 (0.49–0.64) 0.55 (0.47–0.63)
  Wimmer 2014 0.65 (NR) Stroke or death 0.53 (0.46–0.60) 0.53 (0.46–0.60)
  Bennett 2015a 0.70 (NR) Stroke or death 0.56 (0.47–0.65) 0.56 (0.47–0.65)
 Bennett 2015b 0.74 (NR) Stroke or death 0.52 (0.47–0.57) 0.52 (0.47–0.57)
  Chaudhry 2016 NR Stroke, cardiac complications, 
or death
0.49 (0.42–0.57) 0.49 (0.43–0.56)
  Eslami 2016 0.71 (NR) Stroke, MI, death, or discharge 
to rehabilitation facility
0.54 (0.48–0.61) 0.52 (0.46–0.59)
CAS long-term models
  Hoke 2012* 0.79 (NR) Mortality 0.67 (0.63–0.71) NA
  Cheng 2016 0.66 (NR) Stroke, MI, or death 0.61 (0.57–0.65) NA
CEA long-term models
  van Lammeren 2012 0.69 (0.64–0.73) Stroke, MI, or death from 
cardiovascular causes
0.59 (0.54–0.63) NA
  Conrad 2013* 0.74 (NR) Mortality 0.67 (0.63–0.71) NA
  Wallaert 2013* NR Mortality 0.66 (0.59–0.73) NA
  Gates 2015 NR Short-term stroke, MI, or death, 
long-term ipsilateral stroke or 
death from neurological causes
0.60 (0.55–0.65) NA
CAS and CEA long-term model
  Alcocer 2013 NR Mortality 0.60 (0.57–0.64) NA
Risk of stroke or death within 30 d after the procedure was used as primary outcome for all short-term outcome models; the original outcome measure 
was used for all long-term outcome models. CAS indicates carotid artery stenting; CEA, carotid endarterectomy; CI, confidence interval; MI, myocardial 
infarction; NA, not applicable; and NR, not reported.
*Externally validated with data from EVA-3S (Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis) and ICSS 
(International Carotid Stenting Study) only.
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Discussion
In this study, we assessed predictive performance of 30 exist-
ing prediction models for short-term and long-term outcome 
after carotid revascularization in a large population of patients 
with symptomatic ICA stenosis. Most prediction models for 
short-term outcome after CAS or CEA had poor ability to dis-
criminate between patients who will and will not get an event. 
In addition, most calibration curves were narrow (ie, absolute 
risk difference between patients in the lowest and highest risk 
groups was small), and risk was overestimated in the high-
est risk categories. The long-term outcome models showed 
slightly better external performance compared with short-term 
outcome models, but most of them were originally developed 
to predict mortality. Hence, these prediction models cannot 
predict which patients have a higher long-term stroke risk 
despite CAS or CEA, and therefore, are not specific for out-
come prediction after carotid revascularization.
Differences in study population characteristics between 
the development cohorts and the validation population may 
have contributed to the poor external performance of most 
models. Most models were developed in observational cohorts 
of both symptomatic and asymptomatic patients, whereas they 
were validated in a trial population of symptomatic patients. 
Trial populations are probably more homogenous and might 
have lower mean absolute complication risks than study pop-
ulations from observational cohort studies because of strict 
inclusion and exclusion criteria and are therefore less repre-
sentative for the total patient population undergoing CAS or 
CEA. Also, the proportion of patients with vascular risk fac-
tors or (cardiac) comorbidities might have been different in 
the validation population, which reduces usefulness of such 
characteristics to distinguish between someone with and with-
out the outcome. However, most models showed only moder-
ate discrimination in the development cohorts (Table); thus, 
we did not expect to find a model with excellent predictive 
performance in the validation population.
Another reason for the poor external performance could 
be that clinicians have already identified the high-risk patients 
for CAS or CEA and have avoided treating these patients. 
Consequently, the risk difference in the remaining eligible 
patients who undergo the intervention is small, which makes 
it difficult to identify a high-risk subset. It is mathematically 
impossible to assess this explanation because data on the 
outcome of patients that did not undergo CAS or CEA are 
absent. Nevertheless, our results suggest that among those 
eligible for CAS or CEA, identification of a high-risk subset 
is currently impossible.
Missing data in the validation population may be a third 
reason for the poor external performance. In the validation 
population, zeros were inserted for predictors that were 
unavailable. Also, proxies were used if no direct match was 
available in the validation population. Therefore, not all pre-
diction models could completely be applied to the validation 
population, which may have influenced predictive perfor-
mance adversely.
Although external validation is an essential step in predic-
tion model development, only 4 of the 30 included models 
had been externally validated in an independent patient popu-
lation before; 2 were externally validated in the same article 
in which their development was described (Alcocer 2013 and 
Cheng 2016),15,16 and the other 2 had each been validated 
twice in independent validation studies (Rothwell 1999 and 
Tu 2003).17–20 Our findings are similar to the findings of these 
previous studies, except that the discriminative performance 
of the Tu 2003 and Cheng 2016 models was slightly better 
in the previous external validations. A calibration plot was 
reported for only one of the previous external validation stud-
ies,18 whereas we reported calibration plots for each prediction 
model that we validated.
Our study has several strengths. We performed an exten-
sive external validation study of all existing prediction models 
for clinical outcome after carotid revascularization that we 
identified with a literature review. Moreover, all models were 
validated in the same study population, which allows for direct 
comparison of their predictive performance. Furthermore, 
multiple imputation was used to handle missing data, which 
is preferable to complete case analysis.21
Nevertheless, some limitations need to be mentioned. 
First, our validation population consisted of symptomatic 
ICA stenosis patients, whereas the majority of the models 
was developed for both symptomatic and asymptomatic 
patients. Symptomatic and asymptomatic patients have a 
different absolute complication risk after CAS or CEA and 
have different characteristics that may influence this risk 
(eg, type of most recent ipsilateral ischemic event, time 
between most recent event and procedure). Moreover, study 
populations that consist of both symptomatic and asymptom-
atic patients have more variation in patient characteristics 
and absolute complication risk compared with our valida-
tion population. External validation of prediction models 
developed for asymptomatic patients or both symptomatic 
and asymptomatic patients in a population of symptomatic 
patients may have reduced predictive performance of these 
models. Second, the amount of systematically missing pre-
dictors was considerable in some of the individual trials. 
However, we performed multiple imputation to account for 
these missing variables. Moreover, predictive performance 
in the total population after multiple imputation was com-
parable to the performance in the complete case analysis. 
Third, some variables were unavailable in the validation 
population and were assigned a value of zero for all patients; 
consequently, these variables could not add to the predic-
tive ability of the models. Last, we could not externally vali-
date 3 prediction models, because insufficient information 
was reported or insufficient data were available to externally 
validate these models.
The aim of this study was to assess external performance 
of prediction models for clinical outcome after carotid revas-
cularization based on readily available patient characteristics. 
Yet, none of the prediction models showed good discrimina-
tion and consistently good calibration in our validation popu-
lation, whereas calibration is especially important if the aim 
of the model is to identify patients at different levels of risk. 
Consequently, we cannot recommend the use of any of these 
models in clinical practice. External validation of the predic-
tion models in other study populations is demanded, prefer-
ably in observational cohorts of patients undergoing CAS or 
CEA and with sufficient information available on predictors 
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and outcomes. In case external performance of the existing 
prediction models in other study populations would remain 
poor, new prediction models for short-term outcome after 
CAS or CEA need to be developed considering the most 
important predictors from our previous literature review4 as 
candidate predictors. Such models may eventually be com-
bined with long-term outcome models to estimate absolute 
risk of postprocedural complications after carotid revascular-
ization and optimize decision-making between CAS and CEA 
in individual patients.
Conclusions
In this external validation study, prediction models with read-
ily available patient characteristics poorly predicted short-
term and long-term outcome after carotid revascularization in 
a trial population of patients with symptomatic carotid steno-
sis. Further external validation of existing prediction models 
or development of new prediction models—preferably in a 
more heterogeneous study population with sufficient infor-
mation on predictors and outcomes—is needed to accurately 
estimate risks after CAS or CEA in individual patients with 
carotid stenosis.
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Description of literature review
1
 
 
Literature search 
 
We performed a literature search in PubMed and Embase on December 22, 2016, for studies that 
described a prediction model for short-term or long-term outcome after carotid artery stenting 
(CAS) or carotid endarterectomy (CEA). The search syntax consisted of synonyms for ‘carotid 
artery stenting OR carotid endarterectomy’ AND ‘prediction model’ AND ‘vascular events’.  
 
We included studies that described a prediction model that predicted risk of vascular events after 
CAS or CEA in patients with symptomatic or asymptomatic carotid artery stenosis. These studies 
had to present either a prediction model with regression coefficients and a measure of predictive 
performance or a risk score (not only a multivariable analysis of predictors), and had to include at 
least one baseline patient characteristic in the final prediction model.  
 
Critical appraisal and data extraction was performed with a standardized form based on the 
CHARMS checklist.
2
  
 
Results  
 
Our search yielded 37 records that described 46 unique prediction models; 11 models for patients 
who underwent CAS, 34 models for patients who underwent CEA, and 1 model for patients who 
underwent CAS or CEA. Thirty-six of these models predicted short-term outcome and 10 models 
predicted long-term outcome.  
 
We excluded 13 of the 46 prediction models for the current analysis. Ten of these models used 
procedural characteristics,
3–11
 three models predicted risk of myocardial infarction or other 
cardiac complications,
12–14
 and three did not provide sufficient information to validate the 
model.
15–17
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Description of proxies used in the validation population 
 
Predictors  
 
We used proxies for 16 predictors. Nonwhite race (defined as blacks or Hispanics) was only 
collected in CREST, which was conducted in the USA. The other three trials were mainly 
conducted in Europe; therefore, we assigned a value of zero (absent) for the variable nonwhite 
race for patients from these three trials.  
 
We used history of insulin-dependent or non-insulin dependent diabetes mellitus as proxy for the 
predictor diabetes or impaired glucose tolerance and for the predictor diabetes with inadequate 
glycemic control (HbA1c >7%). We used serum creatinine values to calculate glomerular 
filtration rates (GFR) with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation, and used a threshold of GFR <15 ml/min/1.73m
2
 as need for dialysis.
18
  
 
Occurrence of transient ischemic attack (TIA) as qualifying event before the procedure was used 
as proxy for history of TIA. We approximated history of stroke with residual symptoms by 
combining a history of stroke with a modified Ranking Scale (mRS) score at baseline of 1 or 
higher; history of stroke without residual symptoms was approximated by combining a history of 
stroke and an mRS score at baseline of 0. We used an mRS score at baseline ≥3 as proxy for 
dependent functional status and a score of 4 or 5 as proxy for patient admission from nursing 
home. 
 
We used history of coronary heart disease (composite of history of angina, myocardial infarction, 
or coronary revascularization) as proxy for presence of physiologic high-risk characteristics 
(which included heart failure, left ventricular ejection fraction <30%, unstable angina or 
myocardial infarction 30 days before surgery). History of peripheral vascular disease was used as 
proxy for large artery atherosclerosis. Presence of contralateral stenosis 70-99% or occlusion 
was available only as dichotomous variable in the validation population and was used as proxy 
for contralateral stenosis ≥50%.  
 
We assigned a value of zero for malignant disease, valvular heart disease, previous ipsilateral 
CEA, emergency procedure, and impending major surgery because these characteristics were 
exclusion criteria in some or all of the four trials. 
 
Outcome measures  
 
Disabling stroke was defined as an mRS score ≥3 30 days or later after stroke onset in the four 
trials and was used as proxy for major stroke (i.e. fatal stroke or stroke lasting longer than 7 days) 
for the two prediction models that were originally developed to predict this outcome.
19,20
 
Duration of in-hospital stay after the procedure was not collected in EVA-3S. Therefore, we 
used a period of 30 days after the procedure as duration of follow-up for all short-term outcome 
models.  
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Table I. Predictors used in prediction models for short-term outcome after CAS, short-term outcome 
after CEA, and long-term outcome 
 CAS short-term CEA short-term 
 
Predictors 
Hofmann 
2006a21 
Hofmann 
2006b21 
Hawkins 
201222 
Wimmer 
201223 
McCrory 
199324 
Kucey 
199825 
Rothwell 
199919 
Kuhan 
200120 
Age X X X X X X 
  
Sex  
     
X X 
 
Race 
        
Smoking 
        
Diabetes mellitus X X 
     
X 
High blood pressure 
    
X 
 
X 
 
History of stroke or TIA 
        
History of stroke 
  
X X 
    
History of stroke with residual symptoms 
        
History of stroke without residual symptoms 
        
History of TIA 
   
X 
    
Cerebral degeneration*  
        
Myocardial infarction 
   
X 
    
Angina 
    
X 
   
Heart failure 
        
Coronary artery disease 
        
Valvular heart disease 
        
Atrial fibrillation 
  
X 
     
Cardiomyopathy* 
        
Results of cardiac stress test* 
        
Heart disease† 
       
X 
Peripheral vascular disease or surgery 
      
X 
 
Large artery atherosclerosis 
        
Prior coronary intervention 
        
Any prior vascular surgery* 
        
COPD or dyspnea* 
        
Renal function or dialysis 
   
X 
    
Malignant disease 
        
Prior neck radiation* 
        
Bleeding disorder* 
        
Symptomatic ICA stenosis X 
 
X 
  
X 
  
Type of preoperative event
‡
 
    
X 
  
X 
Dependent functional status 
        
Contralateral ICA stenosis X X 
      
Contralateral ICA occlusion 
        
Anatomical characteristics on imaging* 
 
X 
 
X X 
   
Laboratory characteristics* 
        
Antiplatelet use 
        
Statin use 
        
Antihypertensives use* 
        
Previous ipsilateral CEA 
  
X 
     
Emergency procedure 
        
Carotid revascularization prior to other 
surgery*    
X 
 
X 
    
Side of procedure 
   
X 
 
X 
  
Operator experience* 
     
X 
  
Physiologic high-risk characteristic 
        
ASA classification*  
        
Impending major surgery 
  
X 
     
Total number of predictors 4 4 6 10 7 6 3 3 
Number of predictors unavailable in 
validation population 
0 1 0 4 3 2 0 0 
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Table I. Predictors used in prediction models for short-term outcome after CAS, short-term outcome 
after CEA, and long-term outcome (continued) 
 CEA short-term 
 
Predictors 
Tu 
200326 
Matsen 
200527 
Goodney 
200828 
Calvillo-
King 
2010a29 
Calvillo-
King 
2010b29 
Calvillo-
King 
2010c29 
Bekelis 
2013a13 
Bekelis 
2013b13 
Age  X X 
   
X 
 
Sex   
  
X X X X 
 
Race  
  
X X X 
  
Smoking  
       
Diabetes mellitus X 
       
High blood pressure  
       
History of stroke or TIA X 
  
X X X 
  
History of stroke  
       
History of stroke with residual symptoms  
     
X X 
History of stroke without residual symptoms  
     
X X 
History of TIA  
     
X X 
Cerebral degeneration*   X 
      
Myocardial infarction  
     
X 
 
Angina  
     
X X 
Heart failure X 
 
X X 
 
X X 
 
Coronary artery disease  
  
X X X 
  
Valvular heart disease  
  
X X X 
  
Atrial fibrillation X 
       
Cardiomyopathy*  X 
      
Results of cardiac stress test*  
       
Heart disease†  
       
Peripheral vascular disease or surgery  
     
X 
 
Large artery atherosclerosis  X 
      
Prior coronary intervention  
       
Any prior vascular surgery*  
       
COPD or dyspnea*  
     
X 
 
Renal function or dialysis  
     
X 
 
Malignant disease  
       
Prior neck radiation*  
       
Bleeding disorder*  X 
      
Symptomatic ICA stenosis  
       
Type of preoperative event
‡
  
 
X 
     
Dependent functional status  
  
X X X 
  
Contralateral ICA stenosis  
  
X X 
   
Contralateral ICA occlusion X 
 
X 
     
Anatomical characteristics on imaging*  
       
Laboratory characteristics*  
       
Antiplatelet use  
 
X 
     
Statin use  
       
Antihypertensives use*  
       
Previous ipsilateral CEA  
       
Emergency procedure  
 
X 
     
Carotid revascularization prior to other 
surgery* 
 
       
Side of procedure  
       
Operator experience*  
       
Physiologic high-risk characteristic  
       
ASA classification*   
       
Impending major surgery  
       
Total number of predictors 5 5 6 8 7 7 11 4 
Number of predictors unavailable in 
validation population 
0 3 0 0 0 0 1 0 
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Table I. Predictors used in prediction models for short-term outcome after CAS, short-term outcome 
after CEA, and long-term outcome (continued) 
 CEA short-term 
 
Predictors 
Bekelis 
2013c13 
Gupta 
201330 
Wimmer 
201431 
Bennett 
2015a3 
Bennett 
2015b3 
Chaudhry 
201632 
Eslami 
201633 
Age X X X 
  
X X 
Sex  
       
Race 
       
Smoking 
     
X 
 
Diabetes mellitus 
  
X 
   
X 
High blood pressure 
       
History of stroke or TIA 
       
History of stroke 
       
History of stroke with residual symptoms X 
      
History of stroke without residual symptoms 
       
History of TIA 
       
Cerebral degeneration*  
       
Myocardial infarction X 
 
X 
    
Angina 
 
X 
     
Heart failure X 
 
X 
  
X X 
Coronary artery disease 
       
Valvular heart disease 
       
Atrial fibrillation 
     
X 
 
Cardiomyopathy* 
       
Results of cardiac stress test* 
       
Heart disease† 
       
Peripheral vascular disease or surgery X X X 
   
X 
Large artery atherosclerosis 
       
Prior coronary intervention 
       
Any prior vascular surgery* 
       
COPD or dyspnea* X X 
     
Renal function or dialysis X 
    
X 
 
Malignant disease 
       
Prior neck radiation* 
       
Bleeding disorder* 
       
Symptomatic ICA stenosis 
  
X 
  
X X 
Type of preoperative event
‡
 
   
X 
   
Dependent functional status 
 
X 
    
X 
Contralateral ICA stenosis 
   
X X 
  
Contralateral ICA occlusion 
  
X 
   
X 
Anatomical characteristics on imaging* 
       
Laboratory characteristics* 
       
Antiplatelet use 
       
Statin use 
       
Antihypertensives use* 
       
Previous ipsilateral CEA 
       
Emergency procedure 
   
X 
  
X 
Carotid revascularization prior to other 
surgery*        
Side of procedure 
       
Operator experience* 
       
Physiologic high-risk characteristic 
   
X 
   
ASA classification*  
    
X 
  
Impending major surgery 
       
Total number of predictors 7 6 7 4 2 6 8 
Number of predictors unavailable in 
validation population 
1 2 0 0 1 0 0 
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Table I. Predictors used in prediction models for short-term outcome after CAS, short-term outcome 
after CEA, and long-term outcome (continued) 
 CAS long-term CEA long-term CAS and CEA 
long-term 
 
Predictors 
Hoke  
201234 
Cheng 
201635 
Van 
Lammeren 
201236 
Conrad 
201337 
Wallaert 
201338 
Gates  
201539 
Alcocer  
201340  
Age X X X X X X X 
Sex  
       
Race 
       
Smoking 
  
X 
 
X 
  
Diabetes mellitus X X 
 
X X X X 
High blood pressure 
  
X 
    
History of stroke or TIA 
     
X 
 
History of stroke 
       
History of stroke with residual symptoms 
       
History of stroke without residual symptoms 
       
History of TIA 
       
Cerebral degeneration*  
       
Myocardial infarction 
       
Angina 
       
Heart failure X X 
  
X X 
 
Coronary artery disease 
  
X X 
   
Valvular heart disease 
       
Atrial fibrillation 
       
Cardiomyopathy* 
       
Results of cardiac stress test* 
       
Heart disease† 
       
Peripheral vascular disease or surgery X 
 
X 
    
Large artery atherosclerosis 
       
Prior coronary intervention 
      
X 
Any prior vascular surgery* 
       
COPD or dyspnea* 
   
X X X X 
Renal function or dialysis 
  
X X X 
 
X 
Malignant disease 
 
X 
     
Prior neck radiation* 
   
X 
   
Bleeding disorder* 
       
Symptomatic ICA stenosis 
 
X X 
    
Type of preoperative event
‡
 
       
Dependent functional status 
     
X 
 
Contralateral ICA stenosis 
  
X 
 
X X 
 
Contralateral ICA occlusion X 
      
Anatomical characteristics on imaging* 
       
Laboratory characteristics* X 
      
Antiplatelet use 
       
Statin use 
   
X X 
  
Antihypertensives use* 
  
X 
    
Previous ipsilateral CEA 
       
Emergency procedure 
       
Carotid revascularization prior to other 
surgery*        
Side of procedure 
       
Operator experience* 
       
Physiologic high-risk characteristic 
       
ASA classification*  
       
Impending major surgery 
       
Total number of predictors 7 5 8 7 8 7 5 
Number of predictors unavailable in 
validation population 
2 0 1 2 1 1 1 
8 
 
Some models used multiple predictors of the same type (e.g. for anatomical characteristics on angiogram). 
*Data not available in any of the four trials; therefore, a value of zero was assigned. 
†Composite of angina, myocardial infarction, heart failure, or cardiac arrhythmia. 
‡Amaurosis fugax, transient ischemic attack, or ischemic stroke.  
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy; TIA, transient ischemic attack; COPD, chronic obstructive 
pulmonary disease; ICA, internal carotid artery; ASA, American Society of Anesthesiologists.
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Table II. Description of development cohorts of prediction models for short-term outcome after CAS, short-term outcome after CEA, and long-
term outcome 
Prediction 
model 
Country of 
recruitment 
Recruitment 
period 
Data source 
Number of 
including 
centers 
Asymptomatic/ 
symptomatic 
patients 
Predicted outcome 
Prediction 
horizon 
Model 
type 
Number of 
events/ 
patients (%) 
Symptomatic 
patients, 
% 
Age, 
mean (SD) 
Male sex, 
% 
CAS short-term models                    
Hofmann 
2006a21 
Austria 1997-2005 Secondary care hospital 1 Both Stroke, MI or death ≤30 days after 
procedure 
Logistic 26/606    
(4.3) 
36.1 71.5 (NR)* 67.3 
Hofmann 
2006b21 
Austria 1997-2005 Secondary care hospital 1 Both Stroke, MI or death ≤30 days after 
procedure 
Logistic 26/606    
(4.3) 
36.1 71.5 (NR)* 67.3 
Hawkins 
201222 
USA 2005-2011 National carotid 
revascularization 
registry 
173 Both Stroke or death Postprocedural 
in-hospital 
Logistic 271/11,122 
(2.4)† 
41.4 70.6 (NR) 61.5 
Wimmer 
201223 
USA, Canada 2006-2010 Stenting and 
Angioplasty with 
Protection in Patients at 
High-Risk for 
Endarterectomy 
(SAPPHIRE) worldwide 
study 
364 Both Stroke or death ≤30 days after 
procedure 
Logistic 366/10,186 
(3.6) 
29.8 72.3 (±9.7) 61.1 
CEA short-term models 
      
     
McCrory 
199324 
USA 1988-1990 Discharge database of 
12 academic hospitals 
12 Both Stroke, MI or death Postprocedural 
in-hospital 
Other 27/388    
(6.9)‡ 
59.0‡ 67 (±8.4)§ 65.0
§ 
Kucey 199825  Canada 1994-1996 Discharge database of 8 
secondary care hospitals 
8 Both Stroke or death ≤30 days after 
procedure 
Logistic 81/1,280  
(6.3) 
73.3 NR 66.1 
Rothwell 
199919 
Europe 1981-1994 European Carotid 
Surgery Trial (ECST) 
100 Symptomatic Major stroke or 
death 
≤30 days after 
procedure 
Logistic 84/1,203  
(7.0)|| 
100 62.5 (±8.1)# 71.9
# 
Kuhan 200120 UK 1992-1999 Two vascular surgery 
units from one academic 
hospital 
2 Both Major stroke or 
death 
≤30 days after 
procedure 
Logistic 29/741    
(3.9) 
87.2 68 (NR)* 60.4 
Tu 200326 Canada 1994-1997 Regional hospital 
discharge database 
34 Both Stroke or death ≤30 days after 
procedure 
Logistic 362/6,038  
(6.0) 
69.4 68.3 (NR) 65.3 
Matsen 
200527 
USA 1994-2003 Secondary care hospital 1 NR Mortality Postprocedural 
in-hospital 
Logistic 125/23,237 
(0.5) 
NR 70.6 (NR) 54.7 
Goodney 
200828 
USA 2003-2007 Regional vascular 
surgery quality 
improvement database 
11 Both Stroke or death ≤30 days after 
procedure 
Logistic 57/3,092  
(1.8) 
44.0 69.0 (NR) 59.0 
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Table II. Description of development cohorts of prediction models for short-term outcome after CAS, short-term outcome after CEA, and long-
term outcome (continued) 
Prediction 
model 
Country of 
recruitment 
Recruitment 
period 
Data source 
Number of 
including 
centers 
Asymptomatic/ 
symptomatic 
patients 
Predicted outcome 
Prediction 
horizon 
Model 
type 
Number of 
events/ 
patients (%) 
Symptomatic 
patients, 
% 
Age, 
mean (SD) 
Male sex, 
% 
CEA short-term models                    
Calvillo-
King 2010a29 
USA 1998-1999 New York Carotid 
Artery Surgery 
(NYCAS) study 
157 Asymptomatic Stroke or death ≤30 days after 
procedure 
Logistic 200/6,553 
(3.1) 
0 74.5 (±6.6) 
 
54.9 
Calvillo-
King 2010b29 
USA 1998-1999 New York Carotid 
Artery Surgery 
(NYCAS) study 
157 Asymptomatic Stroke ≤30 days after 
procedure 
Logistic 165/6,553 
(2.5) 
0 74.5 (±6.6) 
 
54.9 
Calvillo-
King 2010c29 
USA 1998-1999 New York Carotid 
Artery Surgery 
(NYCAS) study 
157 Asymptomatic Stroke or death ≤30 days after 
procedure 
Logistic 200/6,553 
(3.1) 
0 74.5 (±6.6) 
 
54.9 
Bekelis 
2013a13 
USA 2005-2010 National database >180 Both Stroke, MI or death ≤30 days after 
procedure 
Logistic 994/35,698 
(2.8) 
43.9 71.1 (NR) 59.1 
Bekelis 
2013b13 
USA 2005-2010 National database >180 Both Stroke ≤30 days after 
procedure 
Logistic 585/35,698 
(1.6) 
43.9 71.1 (NR) 59.1 
Bekelis 
2013c13 
USA 2005-2010 National database >180 Both Mortality ≤30 days after 
procedure 
Logistic 267/35,698 
(0.8) 
43.9 71.1 (NR) 59.1 
Gupta 201330 USA 2005-2010 National database >250 Asymptomatic Stroke, MI or death ≤30 days after 
procedure 
Logistic 324/17,692 
(1.8) 
0 72.0 (NR) 57.9 
Wimmer 
201431 
USA 2005-2013 National carotid 
revascularization 
registry 
60 Both Stroke or death Postprocedural 
in-hospital 
Logistic 213/12,889 
(1.7)† 
35.0 70.8 
(±10.6) 
59.0 
Bennett 
2015a3 
USA 2012 National disease-
specific database 
78 Symptomatic Stroke or death ≤30 days after 
procedure 
Logistic 74/1,609 
(4.6) 
100 NR 63.0 
Bennett 
2015b3 
USA 2012 National disease-
specific database 
78 Asymptomatic Stroke or death ≤30 days after 
procedure 
Logistic 43/2,236 
(1.9) 
0 NR 59.6 
Chaudhry 
201632 
USA 2005-2006 All-payer inpatient 
care database 
ca. 1,000 Both Stroke, cardiac 
complications or 
death 
Postprocedural 
in-hospital 
Logistic 1,494/49,411 
(3.0)‡ 
NR 71.1 
(±9.5)§ 
57.6§ 
Eslami 
201633 
USA 2003-2013 Regional vascular 
surgery database 
>35 Both Stroke, MI, death 
or discharge to 
rehabilitation 
facility 
Postprocedural 
in-hospital 
Logistic 389/8,661 
(4.5) 
24.6 69.6 (±9.4) 59.9 
 
  
11 
 
Table II. Description of development cohorts of prediction models for short-term outcome after CAS, short-term outcome after CEA, and long-
term outcome (continued) 
Prediction 
model 
Country of 
recruitment 
Recruitment 
period 
Data source 
Number of 
including 
centers 
Asymptomatic/ 
symptomatic 
patients 
Predicted outcome 
Prediction 
horizon 
Model 
type 
Number of 
events/ 
patients (%) 
Symptomatic 
patients, 
% 
Age, 
mean (SD) 
Male sex, 
% 
CAS long-term models                    
Hoke 201234 Austria 1997-2005 Secondary care 
hospital 
1 Both Mortality Median follow-
up 6.5 years 
Cox 211/602 
(35.0) 
NR 71.0 (NR) 67.6 
Cheng 201635 Taiwan 2004-2009 Random selection from 
national health 
insurance claim 
database 
NR Both Stroke, MI or death 1 year after 
procedure 
Cox 44/317  
(13.9) 
40.4 70.5 (±9.7) 77.9 
CEA long-term models                     
Van 
Lammeren 
201236 
The 
Netherlands 
2002-2009 Secondary care 
hospital and academic 
hospital 
2 Both Stroke, MI or death 
from 
cardiovascular 
causes 
3 years after 
procedure 
Cox 148/1,138 
(13.0) 
83.3 67.3 (±8.9) 69.9 
Conrad 
201337 
USA 1989-2005 Secondary care 
hospital 
1 Asymptomatic Mortality 5 years after 
procedure 
Logistic 536/2,001 
(26.8)† 
0 71 (±8.6) 60.7 
Wallaert 
201338 
USA 2003-2011 Regional vascular 
surgery database 
24 Asymptomatic Mortality 5 years after 
procedure 
Cox 741/4,114 
(18.0) 
0 70.0 (NR) 58.0 
Gates 201539 USA 2003-2011 Regional vascular 
surgery database 
20 Both Short-term stroke, 
MI or death, long-
term ipsilateral 
stroke or death 
from neurological 
causes 
1 year after 
procedure 
Logistic 440/3,098 
(14.2) 
54.3 69.9 (±9.5) 60.3 
CAS and CEA long-term model                    
Alcocer 
201340 
USA 1999-2008 Academic hospital 1 Asymptomatic Mortality 3 years after 
procedure 
Cox 70/506  
(13.8) 
0 69.0 (±9.0) 62.3 
*Median (range). 
†Number of events out of total number of procedures. 
‡In development cohort.  
§In development and validation cohort.    
||Number of patients with 0-69% stenosis who underwent surgery within ECST. 
#Numbers are based on total group of patients with 0-100% ICA stenosis who underwent surgery within ECST.
41
  
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy; MI, myocardial infarction; SD, standard deviation; NR, not reported.  
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Table III. Baseline characteristics and missings in validation population  
  All trials Per trial 
  All (n=4,445) EVA-3S (n=503) SPACE (n=1,136) ICSS (n=1,581) CREST (n=1,225) 
 Characteristic Patients Missings Patients Missings Patients Missings Patients Missings Patients Missings 
 Demographics 
          
Age, mean (SD) 69.2 (±9.2) 0 70.1 (±10.4) 0 68.3 (±8.4) 0 70.0 (±9.1) 0 68.7 (±9.5) 0 
Male sex  3,102 (69.8) 0 379 (75.3) 0 817 (71.9) 0 1,110 (70.2) 0 796 (65.0) 0 
 History of 
          
Hypertension 3,338 (75.4) 16 (0.4) 368 (73.2) 0 859 (75.6) 0 1,091 (69.7) 15 (0.9) 1,020 (83.3) 1 (0.1) 
Current smoking 1,160 (26.3) 34 (0.8) 120 (23.9) 0 316 (27.8) 0 376 (24.0) 15 (0.9) 348 (28.9) 19 (1.6) 
Diabetes 1,112 (25.0) 2 (0.0) 120 (23.9) 0 313 (27.6) 0 342 (21.6) 0 337 (27.6) 2 (0.2) 
Angina 146 (9.3) 2,879 (64.8) 0 503 (100) 0 1,136 (100) 146 (9.3) 15 (0.9) 0 1,225 (100) 
Atrial fibrillation 100 (6.4) 2,879 (64.8) 0 503 (100) 0 1,136 (100) 100 (6.4) 15 (0.9) 0 1,225 (100) 
Myocardial infarction 344 (16.6) 2,376 (53.5) 62 (12.3) 0 0 1,136 (100) 282 (18.0) 15 (0.9) 0 1,225 (100) 
Heart failure 79 (3.8) 2,069 (46.5) 14 (2.8) 0 0 1,136 (100) 65 (4.2) 15 (0.9) 0 1,225 (100) 
Coronary revascularization 69 (13.7) 3,942 (88.7) 69 (13.7) 0 0 1,136 (100) 0 1,581 (100) 0 1,225 (100) 
Peripheral vascular disease 324 (15.7) 2,376 (53.5) 65 (12.9) 0 0 1,136 (100) 259 (16.5) 15 (0.9) 0 1,225 (100) 
Stroke or TIA
*
 713 (34.2) 2,361 (53.1) 186 (37.0) 0 0 1,136 (100) 527 (33.3) 0 0 1,225 (100) 
 Medication use 
          
Antiplatelets 1512 (91.4) 2,790 (62.8) 213 (83.2) 247 (49.1) 0 1,136 (100) 725 (93.3) 804 (50.9) 574 (92.3) 603 (49.2) 
Lipidlowering 806 (49.2) 2,806 (63.1) 248 (49.3) 0 558 (49.1) 0 0 1,581 (100) 0 1,225 (100) 
 Laboratory measures 
          
Creatinine level in mg/dL, mean (SD) 1.1 (±0.3) 3,220 (72.0) 0 503 (100) 0 1,136 (100) 0 1,581 (100) 1.1 (±0.3) 16 (1.3) 
 Anatomical characteristics 
          
Contralateral ICA occlusion 164 (4.1) 454 (10.2) 14 (2.8) 0 35 (4.0) 253 (22.3) 79 (5.0) 10 (0.6) 36 (3.5) 191 (15.6) 
Results are presented as numbers (%), unless stated otherwise.  
*Before the qualifying event. 
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy; TIA, transient ischemic attack; ICA, internal carotid artery; SD, standard deviation.  
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Table IV. Discrimination (c-statistic) of each prediction model in complete cases 
  External validation 
Prediction model 
Number of 
events/patients (%) 
Number of patients 
excluded from complete 
case analysis (%) C-statistic (95% CI)
*
 
CAS short-term models 
Hofmann 2006a 139/1,961 (7.1) 223 (10.2) 0.54 (0.47-0.60) 
Hofmann 2006b 139/1,961 (7.1) 223 (10.2) 0.54 (0.47-0.60) 
Hawkins 2012 55/750 (7.3) 1,434 (65.7) 0.65 (0.58-0.72) 
Wimmer 2012 55/750 (7.3) 1,434 (65.7) 0.62 (0.55-0.68) 
CEA short-term models 
McCrory 1993 25/772 (3.2) 1,489 (65.9) 0.56 (0.45-0.67) 
Kucey 1998  84/2,261 (3.7) 0 (0) 0.53 (0.47-0.59) 
Rothwell 1999 35/1,035 (3.4) 1,226 (54.2) 0.57 (0.48-0.65) 
Kuhan 2001 83/2,197 (3.8) 64 (2.8) 0.55 (0.47-0.62) 
Tu 2003 26/796 (3.3) 1,465 (64.8) 0.51 (0.42-0.61) 
Matsen 2005 37/1,069 (3.5) 1,192 (52.7) 0.46 (0.38-0.55) 
Goodney 2008 33/1,012 (3.3) 1,249 (55.2) 0.53 (0.43-0.63) 
Calvillo-King 2010a 35/1,051 (3.3) 1,210 (53.5) 0.61 (0.53-0.69) 
Calvillo-King 2010b 35/1,051 (3.3) 1,210 (53.5) 0.62 (0.54-0.69) 
Calvillo-King 2010c 36/1,058 (3.4) 1,203 (53.2) 0.63 (0.56-0.68) 
Bekelis 2013a 27/797 (3.4) 1,464 (64.8) 0.61 (0.50-0.71) 
Bekelis 2013b 27/797 (3.4) 1,464 (64.8) 0.62 (0.51-0.72) 
Bekelis 2013c 37/1,057 (3.5) 1,204 (53.3) 0.59 (0.51-0.67) 
Gupta 2013 26/801 (3.2) 1,460 (64.6) 0.51 (0.39-0.64) 
Wimmer 2014 36/1,062 (3.4) 1,199 (53.0) 0.54 (0.45-0.63) 
Bennett 2015a 66/2,002 (3.3) 259 (11.5) 0.56 (0.44-0.67) 
Bennett 2015b 66/2,029 (3.3) 232 (10.3) 0.53 (0.47-0.58) 
Chaudhry 2016 27/812 (3.3) 1,449 (64.1) 0.47 (0.37-0.57) 
Eslami 2016 35/1,051 (3.3) 1,210 (53.5) 0.50 (0.40-0.59) 
CAS long-term models 
Hoke 2012
†
 152/997 (15.2) 12 (1.2) 0.67 (0.63-0.71) 
Cheng 2016 118/1,000 (11.8) 1,184 (54.2) 0.60 (0.55-0.64) 
CEA long-term models 
Van Lammeren 2012
‡
 0/0 2,261 (100) NA 
Conrad 2013
‡
 0/0 2,261 (100) NA 
Wallaert 2013
‡
 0/0 2,261 (100) NA 
Gates 2015 68/1,051 (6.5) 1,210 (53.5) 0.63 (0.56-0.70) 
CAS and CEA long-term model 
Alcocer 2013
‡
 0/0 4,445 (100) NA 
*Risk of stroke or death within 30 days after the procedure was used as outcome for all short-term outcome models; 
the original outcome measure was used for all long-term outcome models. 
†Externally validated with data from EVA-3S and ICSS only.  
‡No patients had data on all variables available. 
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy; CI, confidence interval; NA, not 
applicable. 
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Figure I. Calibration plots before recalibration for the nine prediction models with known intercept or baseline hazard* 
A. CAS short-term models 
  
B. CEA short-term models 
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Figure I. Calibration plots before recalibration for the nine prediction models with known intercept or baseline hazard (continued)* 
C. Long-term model 
 
Risk of stroke or death within 30 days after the procedure was used as primary outcome for all short-term outcome models; the original outcome measure was used for the long-
term outcome model. Calibration plots display the calibration curve in the first imputed dataset; calibration curves in the other multiple imputed datasets were comparable.  
*The original intercept or baseline hazard was reported for 9 out of the 22 models for which we applied the original regression formula.   
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy.     
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Figure II. Calibration plots after recalibration  
A. CAS short-term models 
 
B. CEA short-term models 
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Figure II. Calibration plots after recalibration (continued) 
B. CEA short-term models 
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Figure II. Calibration plots after recalibration (continued) 
C. Long-term models 
 
 
Risk of stroke or death within 30 days after the procedure was used as primary outcome for all short-term outcome models; the original outcome measure was used for all long-
term outcome models. Calibration plots display the calibration curve in the first imputed dataset; calibration curves in the other multiple imputed datasets were comparable.  
Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy.   
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